ONE SHOT COULD BE ENOUGH: WHO Advisers Back a Single-Dose HPV Vaccine to Fight Cervical Cancer
A single-dose HPV vaccine schedule is now the most efficient way to protect against cervical cancer, according to the World Health Organization’s top vaccine advisers. The recommendation came out of the October meeting of WHO’s Strategic Advisory Group of Experts on Immunization (SAGE), as reported by CIDRAP and Health Policy Watch.
Why HPV matters
The human papillomavirus (HPV) causes nearly all cases of cervical cancer. Vaccination before exposure to the virus offers strong protection, which is why programmes focus on young girls.
What SAGE recommended
- One dose for girls aged 9 to 14, as the priority, to improve coverage.
- Countries may consider single-dose vaccination for girls aged 4 to 8 if it helps increase uptake and coverage, as RTÉ reported.
- Then, in order of priority: catch-up for women up to 25, then up to 30; routine vaccination for boys aged 9 to 14; and catch-up for males up to 20.
Why one dose changes the maths
Fewer doses mean fewer clinic visits, lower costs and more people reached with the same supply. With global health budgets under pressure, SAGE’s advice is designed to stretch vaccine supplies further without giving up protection.
What it means for families
SAGE advises WHO; individual countries decide their own schedules. Parents should follow the guidance of their national health authority and talk to their doctor about which schedule applies to their children.
More in our Health section.
Sources: CIDRAP; WHO SAGE, October 2026 meeting.
Featured image: adapted from Bovine Papillomavirus Capsid by Vossman, CC BY-SA 3.0, via Wikimedia Commons (background added).